The Effects Of Vitamin E Supplementation In Patients With Beta Thalassemia On Iron Chelation Therapy

Abstract

Antioxidant vitamins such as vitamin E have been shown to boost the efficacy of iron chelator medicines in patients with ß-thalassemia. The objective of the present study was to evaluate the effects of vitamin E supplementation as an adjuvant therapy on the antioxidant state of beta-thalassemic major patients who were enrolled in the research.Three-month trial including the administration of 400 IU vitamin E orally twice daily was conducted on ß-thalassemic patients who received blood transfusions and oral iron chelator;deferasirox, with a median age of 40 years old were chosen to participate. Measurement of reactive oxygen species (ROS), dinitrothiocyanobenzene reduction were used in conjunction with red blood cell (RBC) reduction; thiobarbituric acid-reactive substances (TBARS) were used in conjunction with serum malondialdehyde were also measured. When comparing patients with thalassaemia to healthy controls, patients with ß-thalassemia exhibited significantly higher baseline levels of serum TBARS and reactive oxygen species (ROS) (P<0.001). They also showed a significant decrease in serum levels of TBARS ,ROSand and RBC after receiving vitamin E therapy(P<0.001). The treatment regimen resulted also in a significant rise in the amount of GSH present in red blood cells. In accordance with our findings, patients with ß-thalassemia experience increased oxidative stress, and treatment with vitamin E specific adjuvant antioxidants may help to prevent this damage. Thus patients may benefit from using vitamin E as a safe and effective supplement to reduce oxidative stress in their bodies. Furthermore, it appears that individuals with beta-thalassemia require a longer period of time to benefit from antioxidant supplements in order to demonstrate clinical hematologic improvement.